Transmucosal NAD+ Delivery
NAD Spray is the nasal spray version of NAD+, for non-injectable protocols. NAD+ is being studied for its role in cellular energy production, metabolism and DNA repair.
Research shows
Practical product identifiers and format details for professional review.
Content
3,000 mg
Format
Nasal Spray
Composition
300 mg/ml per ml
Applied sublingually or intranasally, NAD+ is absorbed through the mucous membranes directly into the bloodstream, avoiding the intestinal degradation that limits oral supplementation efficacy. Mucosal absorption achieves bioavailability significantly superior to oral NMN or NR supplements. Once absorbed, NAD+ enters the same biochemical pathways as injected NAD+: fuelling the electron transport chain, activating sirtuins, and supporting PARP-mediated DNA repair. The spray format supports consistent daily maintenance dosing: sustaining the metabolic and cognitive benefits initiated by injectable protocols.
Based on published research and preclinical data. All benefits are documented under research-grade conditions.
Sublingual and intranasal NAD+ bypasses hepatic first-pass metabolism, achieving absorption directly into systemic circulation through the mucous membranes. While not as efficient as intravenous or subcutaneous routes, mucosal delivery significantly outperforms oral NMN or NR supplements in terms of direct NAD+ availability.
Injectable NAD+ protocols are typically cyclic; the spray provides a practical method for maintaining elevated baseline NAD+ levels between injection sessions. This prevents the trough-cycle decline that can limit the sustained benefits of periodic injectable protocols.
The spray format removes the barriers of needles, reconstitution, and refrigeration for regular travellers and individuals who cannot maintain injectable protocols consistently. It makes daily NAD+ maintenance accessible in any environment.
Regular transmucosal dosing maintains the cognitive clarity, energy, and mood benefits initiated by injectable protocols. Users report that spray top-up prevents the gradual re-decline in energy and focus seen when injectable sessions are spaced more than a few days apart.
Small, distributed doses of NAD+ throughout the day via spray may better support the natural circadian oscillation of NAD+ metabolism than single large doses, potentially improving sleep-wake regulation and hormonal rhythm support.
For individuals new to NAD+ therapy or exploring the protocol before committing to injectables, the spray format provides a lower-barrier introduction to the biochemical effects of NAD+ replenishment.
Explore selected publications and registered trials on NAD Spray, with links to the original sources.
5 publications from the research library.
Evidence type
Publication and key finding
Source
Evidence type
Review
Research relevant to NAD Spray
Publication and key finding
The study reports that increased synthesis of NAD+ promotes protective cell responses, further demonstrating that NAD+ is a regulatory molecule associated with several biochemical pathways.
Antioxidants & redox signaling
Evidence type
Preclinical study
Research relevant to NAD Spray
Publication and key finding
The study reports that in addition, delayed microglial activation normally seen after TBI was reduced by NAD⁺ treatment at 7 days after insult.
Journal of neurotrauma
Evidence type
Preclinical study
Direct NAD Spray evidence
Publication and key finding
The study reports that the NAD+ administration also significantly attenuated ischemia-induced neurological deficits.
Frontiers in bioscience : a journal and virtual library
Evidence type
Review
Direct NAD Spray evidence
Publication and key finding
The study reports that advancing age and many disease states are associated with declines in nicotinamide adenine dinucleotide (NAD+) levels.
The journals of gerontology. Series A, Biological sciences and medical sciences
Evidence type
Review
Direct NAD Spray evidence
Publication and key finding
The study reports that many of these ageing-associated diseases can be slowed down and even reversed by restoring NAD+ levels.
Nature reviews. Molecular cell biology
5 selected studies from the wider trial library, in the order chosen for this product.
NCT04604704
NCT07336836
NCT06812416
NCT07475546
NCT07692633
NAD Spray has an excellent tolerability profile. Mild mucosal irritation (tingling or slight burning sensation at application site) is the most commonly reported effect and typically diminishes with regular use. A mild flush sensation may occur in some individuals due to NAD+ metabolism. The sublingual and intranasal routes are well-established delivery mechanisms with extensive use histories in other compounds. No systemic adverse effects have been documented with transmucosal NAD+ delivery. The spray format avoids all injection-related risks.
This public COA documents one selected production batch and is updated annually. It is not the COA for our latest available batch. Every batch has its own documentation, and partners can request the latest batch COA from our team.
Other products from the same range
